Inhibikase Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Inhibikase Therapeutics

15/08/2023 22:01

* Inhibikase Therapeutics Inc  IKT.OQ  reported a quarterly
adjusted loss of $1.11​​ per share for the quarter ended in
June. The mean expectation of two analysts for the quarter was
for a loss of 92 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Inhibikase Therapeutics Inc's reported EPS for the quarter
was a
loss of $1.11​.
    * The mean earnings estimate of analysts had fallen by
about 13.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Inhibikase Therapeutics Inc shares had fallen by 31.0%
this
quarter and lost 17.0% so far this year.
    * The company reported a quarterly loss of $5.95 million.
    * Wall Street's median 12-month price target for Inhibikase
Therapeutics Inc is $27.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 15 at 09:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.92          -1.11          Missed
 Mar. 31 2023      -0.87          -0.96          Missed
 Dec. 31 2022      -1.14          -1.08          Beat
 Sep. 30 2022      -1.08          -1.08          Met